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Abstract
Purpose The coronary calcium score (CCS) predicts signif-
icant coronary artery disease (CAD) in the general popula-
tion. While moderate chronic kidney disease (CKD) is
associated with high CCS, the use of CCS to predict signif-
icant CAD in these patients is unknown.
Methods A total of 704 patients underwent computed to-
mography coronary angiography for the assessment of CCS
and CAD. Sixty-nine (10 %) patients had moderate CKD,
defined by an estimated glomerular filtration rate (eGFR)
between 30 and 59 mL/min/1.73m2, and the remaining
patients were considered to be without significant CKD
(eGFR≥60 mL/min/1.73m2).
Results Patients with moderate CKD were older, had a higher
CCS, and a higher prevalence of obstructive CAD than
patients without significant CKD. Receiver-operator
curve analysis showed that CCS predicted the presence
of obstructive CAD in both patients with moderate
CKD and those without significant CKD. In patients
with moderate CKD, the optimal cut-off value of CCS
to diagnose obstructive CAD was 140 (sensitivity 73 %
and specificity of 70 %), and is 2.8 fold higher than in
patients without significant CKD (cut-off value=50;
sensitivity 75 % and specificity 75 %).
Conclusion The present results demonstrate that CCS can
predict obstructive CAD in patients with moderate CKD,
although the optimal cut-off value is higher than in patients
without significant CKD.
Keywords Coronary calcification .Chronic kidney disease .
Coronary artery disease
Introduction
In patients with end-stage chronic kidney disease (CKD)
requiring dialysis, cardiovascular mortality is 5 times
higher than in the general population [1]. Furthermore,
studies have demonstrated that even early stages of
CKD, which are more prevalent than end-stage CKD
requiring dialysis [2], are associated with elevated risk
of cardiovascular disease and mortality [3, 4]. Therefore,
accurate detection of cardiovascular disease in patients
with early stages of CKD is important for accurate risk
stratification.
The coronary calcium score (CCS) measured by comput-
ed tomography can predict the presence of significant coro-
nary artery disease (CAD) in the general population [5–10].
While end-stage CKD is associated with elevated CCS as
compared with the general population, several reports have
demonstrated conflicting results in the correlation between
CCS and the presence of significant CAD [10–13].
Moreover, the role of CCS to detect CAD in patients with
moderate CKD, who are at risk for future cardiovascular
events, is unknown. Therefore the aim of the current study
was to evaluate the predictive role of CCS for diagnosing
K. H. Yiu : F. R. de Graaf : J. E. van Velzen :N. A. Marsan :
C. J. Roos :M. K. de Bie : E. E. van der Wall :M. J. Schalij :
J. J. Bax : J. D. Schuijf : J. W. Jukema (*)
Department of Cardiology, Leiden University Medical Center,
Albinusdreef 2, 2333 ZA Leiden, the Netherlands
e-mail: J.W.jukema@lumc.nl
K. H. Yiu :N. A. Marsan : E. E. van der Wall :M. J. Schalij :
J. W. Jukema
The Interuniversity Cardiology Institute of the Netherlands,
Utrecht, the Netherlands
K. H. Yiu :H. F. Tse
Cardiology Division, Department of Medicine,
University of Hong Kong, Hong Kong, People's Republic of China
Neth Heart J (2013) 21:347–353
DOI 10.1007/s12471-013-0409-8
CAD by computed tomography coronary angiography
(CTA) in patients with moderate CKD compared with pa-
tients without significant CKD.
Methods
Study population
The study population consisted of 704 patients who
underwent CCS and CTA assessment for suspected
CAD. Patients were enrolled at the Leiden University
Medical Center. Exclusion criteria included cardiac ar-
rhythmias, severe renal insufficiency (defined as an
eGFR <30 mL/min/m2), known hypersensitivity to io-
dine contrast media and pregnancy.
Classification of moderate chronic kidney disease
Serum creatinine levels were used to assess the eGFR cal-
culated with the Modified Diet in Renal Disease equation
[14]. In order to prevent contrast-induced renal dysfunction
affecting the analysis, only serum creatinine levels obtained
prior to the CTA examination (up to 180 days prior to CTA)
were used. Of note, patients with suspected acute renal
failure (defined by an increase in serum creatinine of
≥0.5 mg/dl in <2 weeks or an increase of >20 % over
baseline if baseline serum creatinine was ≥2.5 mg/dl) were
excluded.
Patients were stratified into those with moderate CKD
and those without significant CKD. The definition of mod-
erate CKD was based on the recommendation from the
National Kidney Foundation [15] using a value of eGFR
between 30 and 59 mL/min/1.73m2. Patients with eGFR
≥60 mL/min/1.73m2 were considered to have no significant
CKD. The mean duration between renal function assessment
and CTA was 37±14 days.
Computed tomography coronary angiography protocol
Examinations of CCS and CTAwere performed using a 64-
row (Aquillion64, Toshiba Medical Systems, Tokyo Japan)
computed tomography scanner. Descriptions of scan param-
eters for CCS and CTA assessment have been published
previously [16, 17].
Data analysis
Post-processing of the CCS and CTA was performed on
dedicated workstations (Vitrea2, Vital Images, Minneapolis,
Minnesota, USA). The CCS was calculated using the
Agatston method and patients were stratified as CCS 0, CCS
1 to 399 and CCS≥400. Coronary anatomy was assessed in a
standardised method by dividing the coronary arteries into 17
segments [18]. All CTAwere interpreted by two experienced
cardiologists blinded to the results of the CCS and eGFR.
Classification of CTA results was made between non-
obstructive and obstructive CAD using a luminal narrowing
≥50% as a threshold for obstructive CAD lesions. In addition,
the number of segments (among the 17 segments) and vessels
(among the 3 coronaries) involved in each category of CAD
(presence of CAD, non-obstructive CAD and obstructive
CAD) was measured.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation and compared using either Student’s t or
Wilcoxon’s rank-sum test as appropriate. Categorical
data are presented as frequencies and percentages and
compared using the chi-square or Fisher’s exact test.
Receiver-operator characteristic (ROC) curve analysis
was performed to determine the value of CCS in diag-
nosing obstructive CAD. The optimal cut-off value was
defined as the maximised value for the sum of sensitiv-
ity and specificity. In addition, the CCS values to diag-
nose obstructive CAD for a predefined 1) sensitivity of
80 % and 2) specificity of 80 % in patients with
moderate CKD and without significant CKD were evaluated.
All statistical analyses were performed using the statistical
package SPSS for Windows (Version 15.0, SPSS, Chicago,
USA). A p value <0.05 was considered to be statistically
significant.
Results
Baseline clinical characteristics
Baseline characteristics of the patient population (704 pa-
tients who underwent CCS and CTA) are shown in Table 1.
The average age of all patients was 56±12 years and 55 %
of patients were male. The mean eGFR for all patients was
84.7±21.5 mL/min/1.73m2. Patients with moderate CKD
were more likely to be older, obese and to have a history
of hypertension while patients without significant CKD
were more likely to be a smoker.
Coronary calcium score
The mean and median CCS of the whole population was
274 and19 respectively. Coronary calcium was absent in
36 % patients, a CCS of 1 to 399 was present in 46 %
patients and CCS≥400 in 18 % patients. The mean and
median CCS of patients with moderate CKD were higher
than in patients without significant CKD. Moreover, patients
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with moderate CKD had a higher prevalence of CCS 1–399
and CCS≥400 than patients without significant CKD
(Table 2).
Computed tomography coronary angiography results
Presence of CAD was detected in 64 % of patients including
non-obstructive CAD in 33 % and obstructive CAD in 31 %
of patients. Patients with moderate CKD had a higher prev-
alence of CAD, increased number of segments and vessels
with CAD as compared with patients without significant
CKD (Table 2). In addition, patients with moderate CKD
had a higher prevalence of non-obstructive CAD although
this observation did not reach statistical significance (p=
0.059). Nevertheless, the number of segments and vessels
involved with non-obstructive CAD was higher in patients
with moderate CKD. In contrast, the prevalence of obstructive
CAD and the number of segments and vessels with obstruc-
tive CAD was similar between patients with moderate CKD
and those without significant CKD.
CTA results in relation to coronary calcium score
The results of CTA in relation to CCS subgroups in
patients with moderate CKD and patients without sig-
nificant CKD are shown in Table 3. Among the two
groups of patients with moderate CKD and patients
without significant CKD, the prevalence of the presence
of CAD, non-obstructive CAD and obstructive CAD
was significantly higher in subgroups of patients with
a higher CCS. Moreover, the number of segments and vessels
involved with the presence of CAD, non-obstructive CAD
and obstructive CAD increased in subgroups of patients with
higher CCS.
Table 1 Baseline demographics
on all patients, patients with
moderate chronic kidney disease
(CKD) and patients without
significant CKD
BMI body mass index; CAD
coronary artery disease; MI
myocardial infarction; PCI
percutaneous coronary
intervention
All (n=704) Moderate
CKD (n=69)
No significant
CKD (n=635)
p value
Age (years) 56±12 62±12 55±12 <0.01
Male gender (%) 385 (54.7) 39 (56.5) 346 (54.5) 0.80
Risk factors (%)
- Diabetes 245 (34.8) 27 (39.1) 218 (34.3) 0.43
- Hypertension 329 (46.7) 43 (62.3) 286 (45) <0.01
- Hypercholesterolaemia 281 (39.9) 35 (50.7) 246 (38.7) 0.07
- Family history of CAD 331 (44.2) 26 (37.7) 285 (44.9) 0.31
- Smoking 149 (21.2) 7 (10.1) 142 (22.4) 0.02
- Obesity BMI >30 kg/m2 150 (21.3) 24 (34.8) 126 (19.8) <0.01
Previous MI (%) 41 (5.8) 4 (5.8) 37 (5.8) 1.00
Previous PCI (%) 44 (6.2) 4 (5.8) 40 (6.3) 1.00
Table 2 Coronary calcium
score (CCS) and computed
tomography coronary
angiography results in patients
with moderate CKD and
without significant CKD
Abbreviations as for Table 1
All patients
(n=704)
Moderate
CKD (n=69)
No significant
CKD (n=635)
p value
Mean CCS 273±760 592±1074 265±712 0.02
Median CCS (Interquatile range) 19 (0, 265) 129 (22, 746) 14 (0, 216)
- CCS 0 (%) 255 (36.2) 11 (15.9) 244 (38.4) 0.01
- CCS 1–399 (%) 320 (45.5) 36 (52.2) 284 (44.7)
- CCS>400 (%) 129 (18.3) 22 (31.9) 107 (16.9)
Presence of CAD (%) 451 (64.1) 56 (81.2) 395 (62.2) <0.01
- Number of segments 3.5±3.8 4.8±4.0 3.3±3.8 <0.01
- Number of vessels 1.7±1.3 2.3±1.1 1.7±1.3 <0.01
Presence of non-obstructive CAD (%) 232 (33.0) 30 (43.5) 202 (31.8) 0.059
- Number of segments 2.8±3.1 3.9±3.4 2.6±3.1 <0.01
- Number of vessels 1.7±1.3 2.2±1.1 1.6±1.3 <0.01
Presence of obstructive CAD (%) 219 (31.1) 26 (37.7) 193 (30.4) 0.22
- Number of segments 0.7±1.4 1.0±1.7 0.7±1.4 0.20
- Number of vessels 0.5±0.9 0.6±0.9 0.5±0.9 0.28
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Prediction of obstructive coronary artery disease
To evaluate the predictive value of CCS for diagnosing ob-
structive CAD in patients with moderate CKD and patients
without significant CKD, ROC curve analysis was performed.
As shown in Fig. 1, CCS predicted the presence of obstructive
CAD in both patients with moderate CKD (area under curve
0.78, p<0.01) and patients without significant CKD (area
under curve 0.82, p<0.01). The individual sensitivity and
specificity of CCS to predict obstructive CAD in patients with
moderate CKD and patients without significant CKD are
shown in Fig. 2. In patients with moderate CKD, the optimal
cut-off value of CCS to diagnose obstructive CAD was 140
(sensitivity 73 % and specificity of 70 %). On the other hand,
the optimal cut-off value of CCS for patients without signif-
icant CKD to diagnose obstructive CAD was 50 (sensitivity
Table 3 Results of computed
tomography coronary angiogra-
phy according to CCS subgroups
in patients with moderate CKD
and without significant CAD
Abbreviations as for Table 1
CCS=0 CCS 1–399 CCS≥400 p value
Moderate CKD
Presence of CAD (%) 2 (18.2) 32 (88.9) 22 (100) <0.01
- Number of segments 0.4±0.9 3.6±2.9 9.1±2.6 <0.01
- Number of vessels 0.4±0.7 2.5±0.8 3.0±0.2 <0.01
Presence of non-obstructive CAD (%) 1 (9.1) 22 (61.1) 7 (31.8) <0.01
- Number of segments 0.2±0.4 3.1±2.6 7.0±2.9 <0.01
- Number of vessels 0.3±0.5 2.4±0.8 2.9±0.4 <0.01
Presence of obstructive CAD (%) 1 (9.1) 10 (27.8) 15 (68.2) <0.01
- Number of segments 0.2±0.6 0.5±1.1 2.1±2.3 <0.01
- Number of vessels 0.1±0.3 1.3±1.1 1.3±1.1 <0.01
Without significant CAD
Presence of CAD (%) 54 (22.1) 235 (82.7) 106 (99.1) <0.01
- Number of segments 0.6±1.4 3.7±3.1 8.7±3.1 <0.01
- Number of vessels 0.5±1.0 2.2±1.0 2.9±0.3 <0.01
Presence of non-obstructive CAD (%) 37 (15.2) 137 (8.2) 28(26.2) <0.01
- Number of segments 0.5±1.2 3.0±2.6 6.5±2.9 <0.01
- Number of vessels 0.5±0.9 2.1±1.0 2.8±0.5 <0.01
Presence of obstructive CAD (%) 17 (7.0) 98 (34.5) 78 (72.9) <0.01
- Number of segments 0.1±0.4 0.6±1.2 2.2±2.2 <0.01
- Number of vessels 0.1±0.3 0.5±0.8 1.4±1.1 <0.01
Fig. 1 Receiver-operator characteristics curve analysis of patients with
moderate chronic kidney disease (CKD) (Panel a) and without signif-
icant CKD (Panel b). The optimal cut-off value of the coronary
calcium score (CCS) to diagnose obstructive coronary artery disease
(CAD) in patients with moderate CKD is 140 (sensitivity 73 % and
specificity 70 %). The optimal cut-off value of CCS to diagnose
obstructive CAD in patients without significant CKD is 50 (sensitivity
75 % and specificity 75 %)
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75 % and specificity 75 %). To achieve a predefined sensitiv-
ity of 80 % for diagnosing obstructive CAD, the required
value of CCS in patients with moderate CKD was higher than
in patients without significant CKD (110 vs. 27, correspond-
ing specificity 60% vs. 70% respectively). Similarly, a higher
CCS was required to achieve a predefined specificity of 80 %
for diagnosing obstructive CAD in patients with moderate
CKD than in patients without significant CKD (345 vs. 90,
corresponding sensitivity 62 % vs. 71 % respectively).
Discussion
The present report demonstrates that patients with moderate
CKD had a higher prevalence, more diffuse and greater
extent of coronary calcium and CAD than patients without
significant CKD. Moreover, CCS predicted the presence of
obstructive CAD in both patients with moderate CKD and
patients without significant CKD. Importantly, the optimal
cut-off value of CCS for predicting the presence of obstruc-
tive CAD was higher in patients with moderate CKD than
patients without significant CKD.
Recent studies using computed tomography demonstrat-
ed that patients with early stages of CKD had a higher
prevalence of CCS and CAD than patients without CKD
[19, 20]. This is in concordance with the present results,
demonstrating a higher prevalence, more diffuse and greater
extent of coronary calcium and CAD in patients with mod-
erate CKD than patients without significant CKD.
Accordingly, these results provided further supporting evi-
dence for the relationship between elevated cardiovascular
risk and moderate CKD [3, 4]. Interestingly, the increased
prevalence of CAD in patients with moderate CKD was
mainly contributed by the presence of non-obstructive
CAD. The observation may partially be explained by the
thickening and calcification in the media layer, instead of
the intima layer, of the coronaries in patients with moderate
CKD, a phenomenon that is classically described as
Mönckeberg’s calcification or medial calcinosis [21, 22].
Therefore, in patients with moderate CKD, the elevated
CCS located in the medial layer may be associated with
non-obstructive coronary atherosclerosis, rather than signif-
icant luminal obstruction [23].
Although the coronary calcification and degree of CAD
differed between patients with and without CKD, a close rela-
tion between CCS and presence of obstructive CAD has been
shown in the general population [24, 25] as well as in patients
with end-stage CKD [10–12]. The present results further
showed that high CCS was associated with higher prevalence,
more diffuse and greater extent of CAD in both patients with
moderate CKD and patients without significant CKD.
In addition to the significant relation with CAD, previous
reports have demonstrated that the use of CCS can predict the
presence of obstructive CAD in the general population [6, 7].
Moreover, few studies have evaluated the predictive role of
CCS for obstructive CAD in patients with end-stage CKD. In
the report by Sharples evaluating 18 patients with CKD re-
quiring dialysis, the presence of CCS was not correlated with
obstructive CAD diagnosed by coronary angiogram [13].
Conversely, Fujimoto et al. demonstrated a CCS value of
1000 provided a sensitivity of 68 % and specificity of 69 %
to diagnose obstructive CAD in 76 patients with CKD requir-
ing dialysis [10]. In addition, Robinson and colleagues
showed a CCS value of 400 provided a sensitivity of 86 %
and specificity of 83 % in diagnosing obstructive CAD in 37
patients with CKD (17 of them requiring dialysis) [12]. While
these studies mainly evaluated patients with end-stage CKD,
none of them explored the role of CCS to predict obstructive
CAD specifically in patients with moderate CKD, which is
more common in the general population [2]. Nonetheless,
patients with moderate CKD have a greater cardiovascular
risk than the general population, highlighting the need for
appropriate strategies to detect obstructive CAD [3, 4]. The
results of the present study have thus confirmed the predictive
role of CCS in diagnosing obstructive CAD in patients with
moderate CKD. However, the optimal cut-off value of CCS
was 2.8 fold higher in patients with moderate CKD than
patients without significant CKD. For the same sensitivity
and specificity to diagnose obstructive CAD, the value of
CCS was consistently higher in patients with moderate CKD
than patients without significant CKD (Fig. 2). The reason for
this observation has not been fully elucidated, but may possi-
bly be explained by the different morphology and distribution
of coronary calcification in patients with and without CKD.
Patients with CKD appear to have more diffuse calcified
plaque burden that tends to be located in the media wall rather
than protruding into the lumen [26]. Therefore, while the
Fig. 2 Sensitivity (dotted lines) and specificity (solid lines) of coronary
calcium score (CCS) to predict CAD in patients with moderate CKD
(blue lines) and patients without significant CKD (red lines). The value of
CCS is higher in patients with moderate CKD than in patients without
significant CKD for a given sensitivity and specificity. Example: a
predefined sensitivity and specificity of 80 % (black lines) would require
a higher CCS in patients with moderate CKD than patients without
significant CKD (110 vs. 27 and 345 vs. 90, respectively)
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relation between elevated CCS and obstructive CAD existed
in patients with moderate CKD, the degree of this relationship
is different as compared with patients without moderate CKD.
Accordingly, the optimal cut-off value of CCS to predict the
presence of obstructive CAD should be different in patients
with moderate CKD as compared with patients without sig-
nificant CKD. However, the exact value of CCS for this
purpose requires further evaluation based on larger study
populations.
Limitation
The present study consisted of patients with moderate CKD
and the predictive role of CCS to diagnose obstructive CAD in
patients with severe CKD (eGFR<30 mL/min/1.73m2) can-
not be extrapolated. Similar to previous evaluations exploring
the CTA results of patients with and without CKD, the present
study confirmed that patients with moderate CKD were older
as compared with patients without significant CKD [17].
However, due to the small population, the independent asso-
ciation between moderate CKD and high CCS/significant
CAD could not be evaluated. Although CCS is proven to be
a valuable tool to detect coronary calcification, it is unable to
differentiate media calcification, which is common in patients
with CKD, from intima calcification. Moreover, whether the
use of computed tomography fractional flow reserve will
provide additional diagnostic information in patients with
CKD would require further studies [27].
Conclusion
The present study demonstrates that CCS predicted the pres-
ence of obstructive CAD in both patients with moderate CKD
and those without significant CKD. More importantly, the
optimal cut-off value and the value of CCS for the same
sensitivity and specificity to diagnose obstructive CAD were
higher in patients with moderate CKD than patients without
significant CKD. Therefore in the clinical setting, a higher cut-
off value of CCS to predict the presence of obstructive CAD is
required in patients with moderate CKD as compared with
patients without significant CKD.
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